Department of Neurology, Washington University School of Medicine, St. Louis, Missouri.
Semin Respir Crit Care Med. 2017 Dec;38(6):760-767. doi: 10.1055/s-0037-1607990. Epub 2017 Dec 20.
This article addresses the intensive care unit (ICU) management of patients with aneurysmal subarachnoid hemorrhage (SAH), with an emphasis on the prevention of cerebral vasospasm and delayed cerebral ischemia (DCI), which are major contributors to morbidity and mortality. Interventions addressing various steps in the development of vasospasm have been attempted, with variable success. Enteral nimodipine remains the only approved measure to potentially prevent DCI. Since oral and intravenous administrations are limited by hypotension, direct administration via sustained-release pellets and intraventricular administration of sustained-release microparticles are being investigated. Studies of other calcium channel blockers have been disappointing. Efforts to remove blood from the subarachnoid space via cisternal irrigation, cisternal or ventricular thrombolysis, and lumbar cerebrospinal fluid drainage have met with limited and variable success, and they remain an area of active investigation. Several interventions that had early promise have failed to show benefit when studied in large trials; these include tirilazad, magnesium, statins, clazosentan, transluminal angioplasty, and hypervolemia.
这篇文章讨论了颅内动脉瘤性蛛网膜下腔出血(SAH)患者的重症监护病房(ICU)管理,重点是预防脑血管痉挛和迟发性脑缺血(DCI),这是发病率和死亡率的主要原因。已经尝试了针对血管痉挛发展各个阶段的干预措施,但成功率各不相同。肠内尼莫地平仍然是预防 DCI 的唯一经过批准的措施。由于口服和静脉给药会导致低血压,因此正在研究通过缓释微球和脑室内给药的方式直接给药。其他钙通道阻滞剂的研究结果令人失望。通过脑池灌洗、脑池或脑室溶栓以及腰椎脑脊液引流从蛛网膜下腔清除血液的努力取得了有限且各不相同的成功,这仍然是一个活跃的研究领域。一些早期有希望的干预措施在大型试验中未能显示出获益,这些措施包括替拉扎特、镁、他汀类药物、氯苯唑酸、经皮腔内血管成形术和高血容量。